Renaissance of cancer therapeutic antibodies
- 14 June 2003
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 8 (11), 503-510
- https://doi.org/10.1016/s1359-6446(03)02714-4
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?Bone Marrow Transplantation, 2002
- Treating Crohn's Disease by Inducing T Lymphocyte ApoptosisAnnals of the New York Academy of Sciences, 2002
- Engineering therapeutic antibodies for improved functionBiochemical Society Transactions, 2002
- Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF‐κB and AP‐1 activation and IL‐8 and VEGF expression in human head and neck squamous cell carcinoma linesInternational Journal of Cancer, 2002
- Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma VaccineThe Journal of Experimental Medicine, 2001
- Rejection of Disseminated Metastases of Colon Carcinoma by Synergism of IL-12 Gene Therapy and 4-1BB CostimulationMolecular Therapy, 2000
- Clinical significance of IgG Fc receptors and FcγR-directed immunotherapiesImmunology Today, 1997
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996
- Antigen-specific human antibodies from mice comprising four distinct genetic modificationsNature, 1994
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975